Quick Answer
Lexaria Bioscience Corp. reported Research And Development Expense of $8.24 million for the year ending 2025.
- Lexaria Bioscience Corp. showed an increase of +249.0% in Research And Development Expense from 2024 to 2025.
- This data is from Lexaria Bioscience Corp.'s annual report (Form 10-K), filed with the SEC on November 28, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $0.00 | Q1 2014: $0.00 | Q2 2014: $0.00 | Q4 2014: $48.0 thousand | Q1 2015: $240.00 | Q2 2015: $107.00 | Q4 2015: $2.0 thousand | Q1 2016: $6.9 thousand | Q2 2016: $158.00 | Q4 2016: $7.3 thousand | Q1 2017: $7.8 thousand | Q2 2017: $8.2 thousand | Q4 2017: $110.4 thousand | Q1 2018: $75.8 thousand | Q2 2018: $93.1 thousand | Q4 2018: $97.0 thousand | Q1 2019: $66.1 thousand | Q2 2019: $231.0 thousand | Q4 2019: $107.5 thousand | Q1 2020: $186.6 thousand | Q2 2020: $24.6 thousand | Q4 2020: $192.3 thousand | Q1 2021: $176.4 thousand | Q2 2021: $454.4 thousand | Q4 2021: $458.7 thousand | Q1 2022: $275.7 thousand | Q2 2022: $752.1 thousand | Q4 2022: $829.5 thousand | Q1 2023: $696.2 thousand | Q2 2023: $1.64 million | Q4 2023: $574.5 thousand | Q1 2024: $245.8 thousand | Q2 2024: $573.1 thousand | Q4 2024: $1.95 million | Q1 2025: $1.69 million | Q2 2025: $2.72 million | Q4 2025: $671.3 thousand.
- Historical annual values: Fiscal year 2025: $8.24 million | Fiscal year 2024: $2.36 million | Fiscal year 2023: $3.67 million | Fiscal year 2022: $1.84 million | Fiscal year 2021: $1.26 million | Fiscal year 2020: $387.1 thousand | Fiscal year 2019: $555.7 thousand | Fiscal year 2018: $492.9 thousand | Fiscal year 2017: $54.2 thousand | Fiscal year 2016: $9.0 thousand | Fiscal year 2015: $146.5 thousand | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: